Lipase

Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma

Retrieved on: 
星期四, 六月 6, 2024
Incidence, Vomiting, Webcast, Patient, Myocarditis, Appetite, Influenza-like illness, Nausea, Arthralgia, Chills, Diarrhea, Melanoma, Headache, REPL, Clinical trial, Cytokine release syndrome, RP1, Nivolumab, Congress, BLA, Lipase, FDA, Rash, RECIST, ASCO, Injury, Myalgia, Fatigue, Weakness, Pharmaceutical industry

WOBURN, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced the topline results from the primary analysis of the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma. The results by independent central review show one-third of patients receiving RP1 plus nivolumab responded to treatment, improving upon the investigator-assessed data presented at ASCO 2024, with all responses lasting greater than 6 months from baseline.

Key Points: 
  • ET
    WOBURN, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced the topline results from the primary analysis of the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma.
  • The results by independent central review show one-third of patients receiving RP1 plus nivolumab responded to treatment, improving upon the investigator-assessed data presented at ASCO 2024, with all responses lasting greater than 6 months from baseline.
  • The primary analysis by independent central review was triggered once all patients had been followed for at least 12 months.
  • The Company plans to submit the full primary analysis data from the anti-PD1 failed melanoma cohort including key secondary endpoint data and subgroups for presentation at an upcoming medical congress.

Spinning the Future of Clean: Cleancult Debuts One-of-a-Kind Laundry Detergent Sheets Leaving Bulky Plastic Bottles Behind

Retrieved on: 
星期二, 二月 13, 2024
Paraben, Enzyme, Phosphate, Phosphorus, Entrepreneurship, Walmart, Environment, Lipase, SLS, Partnership, Dry cleaning

NEW YORK, Feb. 13, 2024 /PRNewswire/ -- Cleancult is solidifying its position as a leader in the plastic waste retail sector with the launch of the world's first concentrated laundry detergent sheets that contain three stain-fighting enzymes to deliver a uniquely powerful clean. Available for purchase on www.Cleancult.com and Amazon, then landing at select Walmart stores nationwide in April and other retailers later this year, the conveniently pre-measured and lightweight sheets come in an innovative 100% plastic-free and recyclable paper drawer box, eliminating the need for wasteful single-use plastic bottles.

Key Points: 
  • Anti-plastic waste cleaning brand powers sustainable laundry cycles with the launch of triple-action laundry sheets, featuring three stain-expelling enzymes on Amazon and at Walmart.
  • "We have taken a mighty, not messy approach with our latest liquidless laundry lineup.
  • "The powerful formula and compact design make these clean sheets the perfect addition to laundry routines and are great to use when traveling."
  • Leaving clothes soft and fresh, the dissolvable sheets are always made without harsh chemicals, including dyes, phosphates, 1,4-dioxane, phthalates, parabens, phosphorus, and SLS.

Global Food Enzymes Market Forecast Report 2024-2030: Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis - Carbohydrate Segment will Dominate - ResearchAndMarkets.com

Retrieved on: 
星期三, 二月 7, 2024
Technology, Retail, Food Tech, Food, Beverage, Plant, Meat, Meal, Life, Bakery, Fermentation, Prostate, Cargill, Environment, Enzyme, Lipase, Nutrient, Investment, Animal, Food industry, Carbohydrate, Health, Advertising, Bread, BASF, Fine chemical

The "Global Food Enzymes Market, Size, Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Food Enzymes Market, Size, Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The meals market is incorporating foods additives to ensure meals protection and protection, leading to the surge of the food enzymes market share.
  • Due to multiplied demand and growth of industries, the demand for food enzymes is anticipated to surpass other business enzymes.
  • As a result, nutritious food manufacturers are progressively adding enzymes into their offerings, propelling the global food enzymes market forward.

Recognize Healthy Weight Week by Incorporating Weight Support Supplement, Nucific Bio-X4, Into Your Routine

Retrieved on: 
星期二, 一月 23, 2024
Weight gain, Meal, Digestion, Weight loss, Diet, Probiotic, Lipase, Sale, Bloating, Fats, Human, Lactobacillus, Protein, Research, Metabolism, Dietary supplement

LOS ANGELES, Jan. 23, 2024 /PRNewswire/ -- Healthy Weight Week is the third week of every January and an annual observance that encourages individuals to adopt balanced lifestyle choices in support of a healthy body weight. But Dr. Amy Lee, a renowned expert in the field, suggests maintaining a healthy weight requires more than diet and exercise— optimizing your digestion is just as important. According to Dr. Lee, using a probiotic supplement can play a significant role in achieving and sustaining a healthy weight.

Key Points: 
  • LOS ANGELES, Jan. 23, 2024 /PRNewswire/ -- Healthy Weight Week is the third week of every January and an annual observance that encourages individuals to adopt balanced lifestyle choices in support of a healthy body weight.
  • But Dr. Amy Lee, a renowned expert in the field, suggests maintaining a healthy weight requires more than diet and exercise— optimizing your digestion is just as important.
  • According to Dr. Lee, using a probiotic supplement can play a significant role in achieving and sustaining a healthy weight.
  • Research suggests these factors can support a healthy metabolism, which can impact weight management.

U.S. FDA Approves Takeda’s HYQVIA® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Retrieved on: 
星期二, 一月 16, 2024
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, CIDP, Patient, CHMP, Itch, Nausea, SCIG, Fatigue, Erythema, European Commission, European, Abdominal pain, Lipase, EMA, Recombinant, Skin, Back pain, Food, Safety, Caregiver, Primary immunodeficiency, Pain, Marketing, Committee, Headache, Absorption, IVIG, Diagnosis, Pharmaceutical industry

Takeda ( TSE:4502/NYSE:TAK ) today announced that the U.S. Food and Drug Administration (FDA) has approved HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent the relapse of neuromuscular disability and impairment in adults.

Key Points: 
  • Takeda ( TSE:4502/NYSE:TAK ) today announced that the U.S. Food and Drug Administration (FDA) has approved HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent the relapse of neuromuscular disability and impairment in adults.
  • Because it is delivered subcutaneously, HYQVIA can be administered by a healthcare professional in a medical office, infusion center or at a patient’s home.
  • “We’re excited that this therapy could offer some adults with CIDP an alternative subcutaneous option that may address some of these challenges and help personalize treatment.”
    HYQVIA is now available as a maintenance therapy for adult patients with CIDP in the U.S.
  • The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for HYQVIA for CIDP throughout the European Union.6

Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers

Retrieved on: 
星期二, 十二月 5, 2023
Chills, CRS, Melanoma, RP1, CRC, Food, Melanoma Research, RECIST, NMSC, Transplant, Diarrhea, FDA, Cytokine release syndrome, Colorectal cancer, SCCHN, Type, RP3, CRR, Fatigue, Headache, Nausea, Itch, Myocarditis, Incidence, Nivolumab, Influenza-like illness, Research, Clinical trial, Injection site reaction, Myalgia, CSCC, Skin cancer, HCC, Weakness, Society, Head, Appetite, RP2, Regeneron Pharmaceuticals, Carcinoma, Investment, Webcast, Patient, Lipase, Angiosarcoma, MCC, Vomiting, Neck, Uveal melanoma, Rash, BLA, Pharmaceutical industry

The CERPASS study was conducted under a Master Clinical Trial Collaboration and Supply Agreement with Regeneron Pharmaceuticals.

Key Points: 
  • The CERPASS study was conducted under a Master Clinical Trial Collaboration and Supply Agreement with Regeneron Pharmaceuticals.
  • The ORR was comparable between the two study groups (52.5% for RP1 plus cemiplimab vs. 51.4% for cemiplimab alone, p=0.692).
  • The registration directed anti-PD1 failed melanoma cohort from the IGNYTE clinical trial includes 140 patients and completed enrollment earlier this year.
  • RP1 monotherapy was well tolerated, and the safety profile was similar to that observed in non-immunocompromised patients with advanced skin cancers.

Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

Retrieved on: 
星期日, 十二月 10, 2023
Health, Surgery, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Fascia, Safety, Kaplan–Meier estimator, Food, Head, Esophagus, BLA, ASH, Lipase, Liver, Disease, Macrophage, Patient, Multimedia, Abstract, FDA, Joint, GVHD, CRS, GI, SNDX, ORR, Chocolate liquor, Development, Death, Mouth, Society, Skin, Biologics license application, Inflammation, Fibrosis, Pharmaceutical industry

The recommended dose of axatilimab for future trials in chronic GVHD is 0.3 mg/kg every two weeks.

Key Points: 
  • The recommended dose of axatilimab for future trials in chronic GVHD is 0.3 mg/kg every two weeks.
  • Organ-specific responses, including complete responses (CRs), were seen across all organs involved at baseline, including lower gastrointestinal (GI), upper GI, esophagus, joints/fascia, mouth, lungs, liver, eyes and skin.
  • Additionally, responses were notable in fibrosis-dominated organs, including the esophagus (78%), joints and fascia (76%), lungs (47%) and skin (27%).
  • "Full results from the AGAVE-201 trial show rapid durable responses documented in all organs and patient subgroups, with significant symptom burden reduction reported by most of these heavily-pretreated patients.

Marine Enzymes Market to increase by USD 54.62 million from 2023 to 2028, Advanced Enzyme Technologies Ltd., Air Liquide SA, Antozyme Biotech Pvt. Ltd., and more among key companies- Technavio

Retrieved on: 
星期四, 十二月 14, 2023
Medicine, Carbohydrate, Drink, BASF SE, Food, USD, BASF, Cosmetics, Lipase, Plasticizer, Geography, Novo Nordisk, Growth, Novozymes, ASA, SE, SEPPIC, Enzyme, Free, Fine chemical

NEW YORK, Dec. 14, 2023 /PRNewswire/ -- The marine enzymes market is expected to grow by USD 54.62 million from 2023 to 2028.

Key Points: 
  • NEW YORK, Dec. 14, 2023 /PRNewswire/ -- The marine enzymes market is expected to grow by USD 54.62 million from 2023 to 2028.
  • Growing demand for food enzymes is notably driving the marine enzymes market.
  • However, factors such as the complex production process of marine enzymes may impede market growth.
  • We provide a detailed analysis of 20 companies operating in the marine enzymes market including Advanced Enzyme Technologies Ltd., Air Liquide SA, Antozyme Biotech Pvt.

Seagen to Highlight Overall Survival Data for PADCEV® and TIVDAK® during Presidential Symposium at ESMO Congress 2023

Retrieved on: 
星期一, 十月 16, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Diabetes, Fatal, Weakness, Female, Skin, PD-L1, Creatinine, DKA, Nausea, Swelling, Keratitis, Pneumonia, Birth, PD-1, Hair, Neutrophil, Male, Peripheral neuropathy, Lipase, Acute kidney injury, Blood, Stevens–Johnson syndrome, Toxic epidermal necrolysis, Diabetic neuropathy, Toxicity, Bulla, Temperature, Appetite, Itch, SJS, Fetus, Cornea, Conjunctivitis, Hyperglycemia, Dermatitis, Evaluation, Hypoxia, Pain, Diabetic ketoacidosis, Pembrolizumab, ILD, Risk, Liver, Lymphocyte, Grade 2, Rash, Erythema, Fatigue, Acral lentiginous melanoma, Pneumonitis, Papule, Incidence, Dysgeusia, Anemia, Cough, Urinary tract infection, Diarrhea, Erythroderma, Periodic breathing, TEN, Patient, MUC, PN, Drug eruption, Septic shock, Pharmaceutical industry, Medical imaging, Palladium

Skin reactions Severe cutaneous adverse reactions, including fatal cases of SJS or TEN occurred in patients treated with PADCEV.

Key Points: 
  • Skin reactions Severe cutaneous adverse reactions, including fatal cases of SJS or TEN occurred in patients treated with PADCEV.
  • When PADCEV was given in combination with pembrolizumab, the incidence of skin reactions, including severe events, occurred at a higher rate.
  • Skin reactions occurred in 72% (all grades) of the 121 patients treated with PADCEV in combination with pembrolizumab in clinical trials.
  • The majority of the skin reactions that occurred with combination therapy included maculo-papular rash, macular rash and papular rash.

Soul Strips Is Restoring Gut Health Through Convenient, Bioavailable Nutrients

Retrieved on: 
星期五, 九月 29, 2023
Edible, Cranberry, Sleep, Human, Nutrient, Irritable bowel syndrome, Absorption, Libido, Crohn's disease, Tablet, The Gutsy Frog, IBS, Immune system, Food, Bacteria, Health, GI, Nanotechnology, Dietary supplement, Lipase

FORT LAUDERDALE, Fla., Sept. 29, 2023 /PRNewswire/ -- Soul Strips is an innovative health brand that has created a unique form of vitamin and mineral supplementation: the oral strip. The Soul Strips team has developed a form of nanotechnology that allows it to infuse edible strips with essential nutrients targeted toward various basic bodily needs. Soul Strips' range of products (which will be available in American markets soon) includes products for the immune system, cognitive health, sleep aid, libido, energy, and more. It also has a pair of adult and children's supplements for stronger gut health.

Key Points: 
  • The Soul Strips team has developed a form of nanotechnology that allows it to infuse edible strips with essential nutrients targeted toward various basic bodily needs.
  • Soul Strips' range of products (which will be available in American markets soon) includes products for the immune system, cognitive health, sleep aid, libido, energy, and more.
  • This combination of efficacy and hyperconvenience makes Soul Strips an ideal way to maintain preventative health — including gut health — through nutraceutical supplementation.
  • In an era when digestive issues are rampant, Soul Strips' digestive supplements offer a convenient and effective way to boost gut health and ensure that the GI tract of adults and children alike are helping rather than hindering their health.